SHERIDAN, WYOMING – May 8, 2025 – Agilent Technologies Inc. (NYSE: A) is set to highlight its groundbreaking solutions and strategic collaborations at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, from April 25-30, 2025. Agilent’s innovative products, including advanced DNA cancer panels, multiomic profiling assays, and cutting-edge companion diagnostics, will take center stage, reflecting the company’s commitment to advancing cancer research and therapeutic development.
Agilent Avida DNA Cancer Panels: Accelerating Liquid Biopsy Insights
One of the key highlights at AACR 2025 will be the Agilent Avida DNA Cancer Panels. These panels, which are based on state-of-the-art next-generation sequencing (NGS) technology, allow for simultaneous DNA and methylation profiling from a single liquid biopsy sample. The expanded portfolio now includes three new DNA panels designed to provide ultra-sensitive detection of cancer-related genomic alterations in circulating cell-free DNA (cfDNA). This enhanced capability enables cancer researchers to obtain critical insights within a single day shift, reducing workflow time and accelerating diagnostic timelines.
- Key Benefits of Agilent Avida DNA Cancer Panels:
- Ultra-sensitive detection of genomic alterations.
- Streamlined workflow with sequencing-ready libraries in just five hours.
- Multiomic insights when paired with Avida methylation panels.
SureSelect Cancer Assays: Comprehensive Profiling for Advanced Diagnostics
Agilent has also forged an innovative partnership with Tagomics to offer comprehensive genomic profiling solutions that combine the Agilent SureSelect Cancer CGP Assay with the Tagomics Interlace™ Multiomics Assay. This collaboration delivers genome-wide epigenetic signatures alongside targeted DNA variant detection, providing researchers with unprecedented multiomic insights into cancer biology.
The Tagomics Interlace™ platform enables novel methylation profiling with minimal sample input and sequencing, making it an invaluable tool for advancing cancer diagnosis and understanding its molecular mechanisms.
- Strategic Advantages of SureSelect and Tagomics Partnership:
- Unbiased approach to epigenetic profiling.
- Combined genomic and epigenetic insights for deeper disease understanding.
- Accelerated cancer research and diagnosis.
Advancing Hematologic Cancer Research with SureSelect Cancer Pan Heme Assay
In another major development, Agilent’s collaboration with Roswell Park Comprehensive Cancer Center has led to the creation of the SureSelect Cancer Pan Heme Assay. This assay provides comprehensive genomic profiling for hematologic malignancies, analyzing both DNA and RNA. The integration of walkaway automation through the Agilent Magnis NGS Prep System, coupled with optimized data analysis powered by QIAGEN Clinical Insight (QCI), significantly enhances laboratory productivity and turnaround time.
- Key Features of the SureSelect Cancer Pan Heme Assay:
- Comprehensive profiling for hematologic malignancies.
- Walkaway automation for improved lab productivity.
- Integrated secondary and tertiary data analysis.
Strategic Collaboration with Abcam for Companion Diagnostics
Agilent’s strategic partnership with Abcam is another highlight at AACR 2025. This collaboration aims to accelerate the development of immunohistochemistry (IHC) companion diagnostics (CDx) using Abcam’s portfolio of over 10,000 recombinant monoclonal antibodies. This collaboration paves the way for Agilent to expedite the creation of custom assays for drug development, thus enhancing the efficacy of early clinical trials.
Educational Session and Networking at AACR 2025
Agilent will host an exclusive educational session at the Exhibitor Spotlight Theater on April 27, 2025, from 1:30 to 2:30 p.m. The session, titled “Revolutionizing Multiomic Profiling: Tagomics’ Interlace Platform and Agilent’s SureSelect Cancer Pan Heme Assay,” will feature insights from industry leaders such as Dr. Robert Neely of Tagomics and Dr. Sean Glenn of Roswell Park Comprehensive Cancer Center.